Clinical Trials Logo

Clinical Trial Summary

The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow transplantation (HBMT) on hematological malignancies are well established.The aim of this prospective cohort trial is to determine if acute graft-versus-host disease (aGVHD) could be decreased with IL2 therapy post HBMT.


Clinical Trial Description

The effects of haploidentical rhG-CSF-mobilized unmanipulated blood and marrow transplantation (HBMT) on hematological malignancies are well established.The aim of this prospective cohort trial is to determine if acute graft-versus-host disease (aGVHD) could be decreased with IL2 therapy post HBMT.low dose of IL-2 (40 million U/m2) will be administered from WBC engraftment to day 90 post haploidentical transplantation. IL-2 will be administered three times a week. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02659657
Study type Interventional
Source Peking University People's Hospital
Contact Xiangyu Zhao
Phone +861088324576
Email zhao_xy@bjmu.edu.cn
Status Recruiting
Phase Phase 2
Start date March 2015
Completion date December 2021

See also
  Status Clinical Trial Phase
Recruiting NCT02241018 - MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD Phase 2/Phase 3
Completed NCT04539470 - Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Phase 1
Terminated NCT02245412 - A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease Phase 2
Completed NCT03497273 - Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects Phase 1
Completed NCT05825833 - Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCT
Not yet recruiting NCT06294678 - Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Phase 3
Not yet recruiting NCT06294691 - Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases Phase 3
Recruiting NCT04285424 - FMT for Steroid Resistant Gut Acute GVHD Early Phase 1
Terminated NCT01903473 - Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) Phase 2
Recruiting NCT02044185 - Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT01765634 - Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease Phase 2
Terminated NCT00282503 - Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease Phase 3
Recruiting NCT01521039 - Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
Terminated NCT03721965 - Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects Phase 1/Phase 2
Not yet recruiting NCT04971551 - A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Phase 2
Completed NCT02743351 - Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT06394895 - Donor Neutrophil Subsets to Predict the Risk of aGVHD
Terminated NCT05673876 - A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) Phase 1
Recruiting NCT02611180 - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease